Lactobacillus plantarum for adults with mild psoriasis
Official title: Evaluating the Safety and Efficacy of Lactobacillus Plantarum in Treating Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Run by Shenzhen People's Hospital · NCT07194200 · Data updated 2026-11-12
This study will test whether taking Lactobacillus plantarum or an inactivated version can improve skin symptoms in adults aged 18–60 with mild psoriasis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Enrollment | 184 (estimated) |
| Sponsor | Shenzhen People's Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Status | Recruiting |
| Started | December 15, 2025 |
| Main results expected | June 25, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07194200 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–60 in good general health with mild plaque psoriasis (PASI <10), no recent medication use, and no other inflammatory skin or serious systemic diseases are the intended participants.
✕Probably not a fit
Patients with moderate-to-severe psoriasis, other psoriasis subtypes, active skin infections, major comorbidities, or who cannot comply with study procedures are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2, randomized, double-blind, placebo-controlled trial at Shenzhen People's Hospital will assign adults with mild psoriasis (PASI <10) to receive live Lactobacillus plantarum, inactivated Lactobacillus plantarum, or placebo. Participants must be 18–60 years old, in good general health, and off other medications for at least six months. The trial will monitor safety and changes in psoriasis severity and skin-related outcomes over the treatment period. The study is designed to explore whether modifying the skin microbiome can reduce inflammation and improve the skin barrier in psoriasis.
Why it matters
Potential benefit: If successful, this approach could provide a microbiome-targeted treatment that reduces psoriasis symptoms with potentially fewer systemic side effects than conventional systemic therapies.
How similar studies have gone: Early preclinical work and small clinical reports suggest microbiome modulation may help psoriasis, but randomized controlled evidence is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Reference to Psoriasis Area and Severity Index (PASI) score \< 10 Patients have been informed of the study details, voluntarily participate, and have signed the informed consent form; Aged 18-60 years with good general health status; No use of any medications within 6 months; No various inflammatory or immune skin diseases, no local infections, and no neuromuscular diseases. Exclusion Criteria: * Patients with other types of psoriasis or severe psoriasis; Those in the active phase of skin diseases or with other serious diseases; Other situations deemed unsuitable for enrollment by the researchers, such as subjects who are untrustworthy, unable to accept or understand the study assessments.
Where it's running
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China Recruiting
Study contacts
- Study coordinator: Jianglin Zhang
- Email: zhang.jianglin@szgospital.com
- Phone: +86 13873143466
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.